Industry
Biotechnology
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Loading...
Open
5.05
Mkt cap
39M
Volume
115K
High
5.47
P/E Ratio
-0.94
52-wk high
12.00
Low
4.80
Div yield
N/A
52-wk low
3.82
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 9:41 am
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 2:44 pm
Portfolio Pulse from Benzinga Newsdesk
October 02, 2024 | 2:54 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 12:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 5:32 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 3:55 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 12:36 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 12:22 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.